The global blood plasma derivatives market size reached US$ 43.2 Billion in 2022. Looking forward, the analyst expects the market to reach US$ 61.9 Billion by 2028, exhibiting a growth rate (CAGR) of 6.1% during 2023-2028.
Blood plasma derivatives are concentrates of specific proteins prepared from plasma that are obtained through fractionation process. Factor VIII, immunoglobulin, albumin, hyperimmune globulin, factor IX and fresh frozen are some of the common blood plasma derivatives. They are rich in proteins, minerals, salts, hormones, vitamins and protease inhibitors, due to which they are widely used to kill viruses that cause hepatitis B, hemophilia A, bleeding disorders, immunodeficiency, hepatitis C, hypogammaglobulinemia, hemophilia B and human immunodeficiency virus (HIV). Apart from this, blood plasma derivatives assist in enhancing nutrition, controlling body temperature and coagulation of blood, maintaining osmotic pressure, enhancing respiration and excretion, and regulating acid-base balance. Blood plasma derivatives are commonly stored at hospitals, clinics, diagnostic centers and blood transfusion centers.
Blood Plasma Derivatives Market Trends:
The increasing geriatric population that are more susceptible to developing infectious diseases are creating a positive outlook for the market. Blood plasma contains immunoglobulins that play an important role in the development of immunity and maintain the osmotic pressure in blood vessels, which further prevents the onset immunodeficiency disorders and hemophilia. Moreover, the widespread product adoption to treat coronavirus disease (COVID-19) patients by convalescent plasma treatment is favoring the market growth. Additionally, various technological innovations in the fractionation process that aids in separating protein concentrates and various components of blood plasma for clinical purposes are providing a considerable boost to the market growth. In line with this, the development of advanced preservation methods, along with the significant improvements in encased procedures for developing targeted therapeutic products are further augmenting the market growth. Other factors, including significant growth in the healthcare industry, increasing awareness regarding blood and plasma donation and the implementation of various government initiatives to promote blood donation camps, are anticipated to drive the market further toward growth.
Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the global blood plasma derivatives market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, application and end user.
Breakup by Type:
Breakup by Application:
Von Willebrand’s Disease
Breakup by End User:
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, CSL Limited, Fusion Health Care Pvt. Ltd., Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, Sanofi S.A. and Takeda Pharmaceutical Company Limited.
Key Questions Answered in This Report:
What was the size of the global blood plasma derivatives market in 2022?
What is the expected growth rate of the global blood plasma derivatives market during 2023-2028?
What are the key factors driving the global blood plasma derivatives market?
What has been the impact of COVID-19 on the global blood plasma derivatives market?
What is the breakup of the global blood plasma derivatives market based on the type?
What is the breakup of the global blood plasma derivatives market based on the end-user?
What are the key regions in the global blood plasma derivatives market?
Who are the key players/companies in the global blood plasma derivatives market?